Company intelligence / Profile preview
Wuhan Zhongsheng Yujin Biomedical
Wuhan, Hubei, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Wuhan Zhongsheng Yujin Biomedical specializes in the production and distribution of blood products, notably anti-human T lymphocyte porcine immunoglobulin. Its lead product has been approved in China since at least the early 1980s for use in preventing and treating transplant rejection. The company operates as a wholly owned subsidiary of the Wuhan Institute of Biological Products, itself part of Sinopharm. Sales data indicate continued commercial activity as recently as 2022–2023.
- Therapeutic areas
- Immunology
- Modalities
- ImmunoglobulinBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Wuhan Zhongsheng Yujin Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wuhan Zhongsheng Yujin Biomedical.